Belgium’s Hyloris Pharmaceuticals has so far enjoyed a fruitful 2020. Having kicked off the year with a funding round that raised €15m ($17.6m) for the value-added medicines developer (Also see "Hyloris Funding Round Raises €15m" - Generics Bulletin, 4 May, 2020.), the firm more recently announced an initial public offering to give it the funding it needs to pursue opportunities through the US hybrid 505(b)(2) regulatory pathway. (Also see "Value-Added Specialist Hyloris Launches IPO" - Generics Bulletin, 3 June, 2020.) This ultimately resulted in proceeds of €61.81m, or approximately €71.08m assuming the exercise in full of the IPO’s over-allotment option.
Now, CEO Stijn Van Rompay tells Generics Bulletin in an exclusive interview, the firm will be able to build on this success by constructing a US commercial infrastructure and bolstering its
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?